Welcome to our dedicated page for Lensar SEC filings (Ticker: LNSR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LENSAR, Inc. filings document operating results and material events for a commercial-stage medical device company focused on robotic laser systems for cataract procedures. Form 8-K reports furnish quarterly and annual earnings releases, including disclosures on ALLY system activity, installed-base trends, and recurring revenue components such as procedure, lease, and service revenue.
The company’s filings also record capital and governance matters, including common stock listed on Nasdaq under LNSR, officer transition disclosures, and material agreements such as the Priority Credit Line Agreement. Amendments to material-event reports provide additional detail on credit-line terms, collateral arrangements, interest-rate mechanics, and default provisions.
LENSAR, Inc. reported quarterly revenue of $13.4 million, down slightly from $14.2 million a year earlier as system sales declined while procedure, lease and service revenue kept recurring revenue at 94% of the total. The company swung to net income of $36.3 million from a $27.3 million loss, driven mainly by a $23.9 million favorable change in warrant liabilities and $10.0 million of acquisition-related income from retaining the terminated Alcon merger deposit, plus a reduction of previously accrued deal costs. Core operations still used $4.3 million of operating cash, leaving $12.5 million in cash and $1.0 million in short-term investments as of March 31, 2026. Management continues to invest in commercialization of its ALLY Robotic Cataract Laser System, notes ongoing macroeconomic and tariff pressures on component costs, and believes current liquidity and expected sales are sufficient for at least the next 12 months.
LENSAR, Inc. reported first quarter 2026 results showing lower revenue but a sharp swing to reported profitability driven by one‑time items. Total revenue was $13.4 million, down 5% from $14.2 million a year earlier, mainly from a $1.8 million decline in system sales partly offset by higher procedure revenue.
Recurring revenue grew 9% to $12.6 million and represented 94% of total revenue, supported by 54,094 procedures and 7 new ALLY System placements, bringing the total installed base to about 440 systems and an ALLY backlog of 11 units. Net income reached $36.3 million, primarily from $10.0 million of acquisition‑related income tied to the terminated merger and $23.9 million of non‑cash income from changes in warrant liabilities, while Adjusted EBITDA was roughly breakeven at a $0.3 million loss. Cash, cash equivalents and investments were $13.5 million as of March 31, 2026.
LENSAR, Inc. filed Amendment No. 1 to its annual report to add full Part III disclosures on directors, executive compensation, ownership, related-party transactions, and auditor fees. As of April 28, 2026, 12,104,328 shares of common stock were outstanding.
North Run Capital and affiliates beneficially own about 55% of LENSAR’s common stock and 45.1% combined voting power, following a $20.0 million 2024 private placement in Series A Convertible Preferred Stock and warrants. CEO Nicholas T. Curtis received $2,344,966 in total 2025 compensation; COO Alan B. Connaughton and CFO Thomas R. Staab earned $1,075,472 and $782,001, respectively.
LENSAR, Inc. announced that Chief Financial Officer Thomas R. Staab, II has notified the company of his intention to resign, effective May 8, 2026. He will continue to serve as the company’s principal financial officer until that transition date. The company states his resignation is not due to any disagreement regarding operations, policies, or practices, and has begun a search for a new Chief Financial Officer.
LENSAR, Inc. is a commercial-stage medical device company focused on advanced laser systems for cataract surgery, led by its ALLY Robotic Cataract Laser System. The ALLY System combines imaging, treatment planning and dual-modality laser capabilities in a compact unit designed for use in an operating room or in-office suite.
The company targets growing global cataract volumes and low current use of lasers, emphasizing improved visual outcomes, especially for patients with astigmatism choosing premium, largely out-of-pocket procedures. LENSAR highlights proprietary AI-driven imaging, Refractive Capsulorhexis, wireless data integration and a sizable patent portfolio as key competitive strengths, while noting risks including termination of a prior merger agreement, ongoing operating losses, regulatory demands, supply-chain pressures and the need for additional capital and continued market adoption of the ALLY System.
LENSAR, Inc. reported fourth quarter and full-year 2025 results showing a stronger recurring revenue base and growing adoption of its ALLY Robotic Cataract Laser System. Total revenue was $16.0 million in Q4 2025 and $58.4 million for 2025, up from $53.5 million in 2024, with recurring revenue reaching $46.3 million, or 79% of total for both Q4 and the year.
Q4 system revenue declined as the company placed 15 ALLY systems, but procedure-based revenue rose, with worldwide 2025 procedure volume up 22% to 206,014. The ALLY installed base grew 48% year over year to about 200 systems, and the combined laser installed base reached roughly 435 systems.
Despite higher acquisition-related costs tied to a previously contemplated merger with Alcon, net loss narrowed sharply in Q4 to $1.5 million versus $18.7 million a year earlier, mainly due to changes in warrant liability fair value. For 2025, net loss was $34.3 million. Cash, cash equivalents and investments totaled $18.0 million at December 31, 2025, and the company notes it will retain a $10.0 million merger deposit following termination of the Alcon transaction, while recognizing significant acquisition-related expenses.
LENSAR, Inc. Chief Financial Officer Thomas R. Staab II exercised stock options to acquire 5,500 shares of common stock at $2.65 per share. Following the transaction, he directly holds 175,959 shares of LENSAR common stock.
The exercised option is part of a grant that vested 25% on January 11, 2024, with the remainder vesting in thirty-six monthly installments, contingent on continued service. This filing reflects a routine compensation-related option exercise rather than an open-market purchase or sale.
LENSAR, Inc. announced that it has terminated its previously agreed merger with Alcon Research, LLC. The parties signed a Termination and Mutual Release Agreement on March 16, 2026, ending the deal and releasing each other from claims related to the merger.
Under the termination terms, LENSAR will retain the $10.0 million deposit that Alcon had provided. LENSAR states it understands the Federal Trade Commission intends to seek to enjoin the acquisition, and that required U.S. regulatory approvals were unlikely before the merger’s outside dates in April or July 2026.
The company says it will continue as an independent medical technology business focused on its ALLY Robotic Cataract Laser System and plans to report fourth quarter and full-year 2025 financial results and a strategic update on March 31, 2026.
LENSAR, Inc. filed an amended report to restate and clarify its disclosure about a new credit facility with Wells Fargo Bank, N.A. The company has entered into a Priority Credit Line Agreement that provides a revolving, non-purpose margin credit line secured by a first-priority lien on a designated brokerage account.
Based on the collateral value in this account, LENSAR may borrow up to $9.2 million. Borrowings accrue interest, at the company’s election, at either a fixed rate based on the Treasury Yield plus a margin over a chosen term, or a variable rate based on SOFR plus a margin. The agreement includes customary events of default tied to missed payments, collateral shortfalls, insolvency proceedings, and related security agreements.
LENSAR, Inc. has entered into a Priority Credit Line Agreement with Wells Fargo Bank, N.A. providing a revolving, non-purpose margin credit facility of up to $50 million, secured by a first-priority lien on a designated brokerage account at Wells Fargo.
Approximately $10 million in collateral has been deposited in this account to support borrowings. The company can choose interest based on either a fixed rate using the Treasury Yield plus a margin, or a variable rate using SOFR plus a margin. The agreement includes customary events of default such as missed payments, failure to post additional collateral, insolvency events, or insufficient collateral value.